• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

印度尼西亚的卫生经济评估:一项评估证据质量和对印度尼西亚卫生技术评估(HTA)指南遵循情况的系统评价

Health economic evaluations for Indonesia: a systematic review assessing evidence quality and adherence to the Indonesian Health Technology Assessment (HTA) Guideline.

作者信息

Chavarina Kinanti Khansa, Faradiba Dian, Sari Ella Nanda, Wang Yi, Teerawattananon Yot

机构信息

Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangkok, Thailand.

出版信息

Lancet Reg Health Southeast Asia. 2023 Mar 31;13:100184. doi: 10.1016/j.lansea.2023.100184. eCollection 2023 Jun.

DOI:10.1016/j.lansea.2023.100184
PMID:37383554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10306002/
Abstract

BACKGROUND

The Government of Indonesia implemented health technology assessment (HTA) to ensure quality and cost control in the National Health Insurance Program (/JKN). The current aim of the study was to improve the usefulness of future economic evaluation for resource allocation by appraising current methodology, reporting, and source of evidence quality of studies.

METHODS

The inclusion and exclusion criteria were applied to search for relevant studies using a systematic review. The methodology and reporting adherence were appraised according to Indonesia's HTA Guideline issued in 2017. The differences in adherence before and after the guideline dissemination were compared using Chi-square and Fisher's exact tests for methodology adherence wherever appropriate, and the Mann-Whitney test for reporting adherence. The source of evidence quality was assessed using evidence hierarchy. Two scenarios of the study start date and the guideline dissemination period were tested using sensitivity analyses.

FINDINGS

Eighty-four studies were obtained from PubMed, Embase, Ovid, and two local journals. Only two articles cited the guideline. No statistically significant difference (P > 0.05) was found between the pre-dissemination and post-dissemination period with respect to methodology adherence, except for outcome choice. Studies during the post-dissemination period showed a higher score for reporting which was statistically significant (P = 0.01). However, the sensitivity analyses revealed no statistically significant difference (P > 0.05) in methodology (except for modelling type, P = 0.03) and reporting adherence between the two periods.

INTERPRETATION

The guideline did not impact the methodology and reporting standard used in the included studies. Recommendations were provided to improve the usefulness of economic evaluations for Indonesia.

FUNDING

The Access and Delivery Partnership (ADP) hosted by the United Nations Development Programme (UNDP) and the Health Systems Research Institute (HSRI).

摘要

背景

印度尼西亚政府实施了卫生技术评估(HTA),以确保国家医疗保险计划(/JKN)中的质量和成本控制。本研究的当前目的是通过评估当前的方法、报告以及研究证据质量的来源,提高未来经济评估对资源分配的有用性。

方法

采用系统评价的方法,应用纳入和排除标准来检索相关研究。根据2017年发布的印度尼西亚HTA指南对方法和报告的依从性进行评估。在适当的情况下,使用卡方检验和费舍尔精确检验比较指南发布前后方法依从性的差异,使用曼-惠特尼检验比较报告依从性的差异。使用证据等级评估证据质量的来源。使用敏感性分析测试了研究开始日期和指南发布期的两种情景。

结果

从PubMed、Embase、Ovid和两家当地期刊中获得了84项研究。只有两篇文章引用了该指南。在方法依从性方面,除了结果选择外,在指南发布前和发布后期间未发现统计学上的显著差异(P>0.05)。在发布后期间的研究报告得分更高,具有统计学显著性(P=0.01)。然而,敏感性分析显示,在两个时期之间,方法(除建模类型外,P=0.03)和报告依从性方面没有统计学上的显著差异(P>0.05)。

解读

该指南并未影响纳入研究中使用的方法和报告标准。为提高印度尼西亚经济评估的有用性提供了建议。

资金来源

由联合国开发计划署(UNDP)和卫生系统研究所(HSRI)主办的获取与交付伙伴关系(ADP)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c9/10306002/4ebecfb2a0ad/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c9/10306002/7b636259e87b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c9/10306002/78ed26922324/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c9/10306002/4ebecfb2a0ad/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c9/10306002/7b636259e87b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c9/10306002/78ed26922324/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4c9/10306002/4ebecfb2a0ad/gr3.jpg

相似文献

1
Health economic evaluations for Indonesia: a systematic review assessing evidence quality and adherence to the Indonesian Health Technology Assessment (HTA) Guideline.印度尼西亚的卫生经济评估:一项评估证据质量和对印度尼西亚卫生技术评估(HTA)指南遵循情况的系统评价
Lancet Reg Health Southeast Asia. 2023 Mar 31;13:100184. doi: 10.1016/j.lansea.2023.100184. eCollection 2023 Jun.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Impact of Indonesia's national health insurance scheme on inequality in access to maternal health services: A propensity score matched analysis.印度尼西亚国家医疗保险计划对获取产妇保健服务不平等的影响:倾向评分匹配分析。
J Glob Health. 2020 Jun;10(1):010429. doi: 10.7189/jogh.10.010429.
5
The influence of Jaminan Kesehatan Nasional (JKN) on the cost of delivery services in Indonesia.印度尼西亚全民健康保险(JKN)对分娩服务成本的影响。
PLoS One. 2020 Jul 2;15(7):e0235176. doi: 10.1371/journal.pone.0235176. eCollection 2020.
6
The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia's Social Health Insurance System.《印度尼西亚实施医疗保险制度下医药政策对药品采购定价的影响》
Value Health Reg Issues. 2020 May;21:1-8. doi: 10.1016/j.vhri.2019.05.005. Epub 2019 Oct 18.
7
Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.试验报告的统一标准(CONSORT)以及医学期刊上发表的随机对照试验(RCT)的报告完整性。
Cochrane Database Syst Rev. 2012 Nov 14;11(11):MR000030. doi: 10.1002/14651858.MR000030.pub2.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Does geographic spending variation exacerbate healthcare benefit inequality? A benefit incidence analysis for Indonesia.地理支出差异是否加剧了医疗保健福利不平等?印度尼西亚的福利归属分析。
Health Policy Plan. 2021 Aug 12;36(7):1129-1139. doi: 10.1093/heapol/czab015.
10
Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).患者报告结局(PRO)在卫生技术评估(HTA)中的信息价值。
GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.

引用本文的文献

1
A Mixed-Methods Assessment of India's Health Technology Assessment Ecosystem.对印度卫生技术评估生态系统的混合方法评估。
Appl Health Econ Health Policy. 2025 Sep 6. doi: 10.1007/s40258-025-00995-4.
2
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force.卫生技术评估指南制定的良好实践:卫生技术评估国际组织、HTAsiaLink及药物经济学与结果研究国际协会特别工作组的报告
Int J Technol Assess Health Care. 2025 Jan 6;40(1):e74. doi: 10.1017/S0266462324004719.
3
Bridging Real-World Data Gaps: Connecting Dots Across 10 Asian Countries.

本文引用的文献

1
An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations.用于为医疗保健中的优先事项设定和资源分配提供信息的主要类型经济评估简介:主要特点、用途和局限性。
Front Public Health. 2021 Aug 25;9:722927. doi: 10.3389/fpubh.2021.722927. eCollection 2021.
2
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia.印度尼西亚转移性结直肠癌(mCRC)患者化疗中添加贝伐珠单抗的经济学评价。
Asian Pac J Cancer Prev. 2021 Jun 1;22(6):1921-1926. doi: 10.31557/APJCP.2021.22.6.1921.
3
弥合现实世界的数据差距:连接10个亚洲国家的数据点。
JMIR Med Inform. 2024 Aug 15;12:e58548. doi: 10.2196/58548.
4
Navigating HTA implementation: a review of Indonesia's revised HTA guideline.卫生技术评估实施的导航:印度尼西亚修订后的卫生技术评估指南综述
Lancet Reg Health Southeast Asia. 2023 Sep 11;17:100280. doi: 10.1016/j.lansea.2023.100280. eCollection 2023 Oct.
Systematic Literature Review of Guidelines on Budget Impact Analysis for Health Technology Assessment.
系统文献综述:卫生技术评估预算影响分析指南。
Appl Health Econ Health Policy. 2021 Nov;19(6):825-838. doi: 10.1007/s40258-021-00652-6. Epub 2021 May 6.
4
Addressing Challenges in Health Technology Assessment Institutionalization for Furtherance of Universal Health Coverage Through South-South Knowledge Exchange: Lessons From Bhutan, Kenya, Thailand, and Zambia.通过南南知识交流促进全民健康覆盖:来自不丹、肯尼亚、泰国和赞比亚的经验教训。解决卫生技术评估体制化面临的挑战
Value Health Reg Issues. 2021 May;24:187-192. doi: 10.1016/j.vhri.2020.12.011. Epub 2021 Apr 7.
5
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.《PRISMA 2020声明:报告系统评价的更新指南》
Syst Rev. 2021 Mar 29;10(1):89. doi: 10.1186/s13643-021-01626-4.
6
Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia.印度尼西亚肾和外周血管疾病并发症患者2型糖尿病(T2DM)治疗的成本效益分析
Healthcare (Basel). 2021 Feb 16;9(2):211. doi: 10.3390/healthcare9020211.
7
A landscape analysis of health technology assessment capacity in the Association of South-East Asian Nations region.东南亚国家联盟地区卫生技术评估能力的态势分析
Health Res Policy Syst. 2021 Feb 11;19(1):19. doi: 10.1186/s12961-020-00647-0.
8
National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison.国家医疗保健经济评估指南:跨国比较
Pharmacoecon Open. 2021 Sep;5(3):349-364. doi: 10.1007/s41669-020-00250-7. Epub 2021 Jan 10.
9
Institutionalizing Evidence-Informed Priority Setting for Universal Health Coverage: Lessons From Indonesia.将证据转化为优先事项,实现全民健康覆盖:来自印度尼西亚的经验。
Inquiry. 2020 Jan-Dec;57:46958020924920. doi: 10.1177/0046958020924920.
10
On discount rates for economic evaluations in global health.关于全球健康经济评估中的贴现率。
Health Policy Plan. 2020 Feb 1;35(1):107-114. doi: 10.1093/heapol/czz127.